ScoreHaematology
Revised International Prognostic Scoring System for myelodysplastic syndromes (IPSS-R)
Classifies MDS into five risk groups by cytogenetics, blasts and depth of cytopenias, with optional age adjustment.
Updated 31 October 2026
When to use it
Adults with primary MDS at diagnosis, before disease-modifying therapy, to guide prognosis and treatment.
What it needs
- Cytogenetic group
- Bone marrow blasts
- Haemoglobin
- Platelets
- Absolute neutrophil count
- Age (optional, for IPSS-RA) (optional)
The points for each answer and the automatic total are in the app.
How to interpret it
| Result | Interpretation |
|---|---|
| < 2 | Very low (≤ 1.5): median survival ≈ 8.8 years |
| 2 to < 3.5 | Low (> 1.5–3): median survival ≈ 5.3 years |
| 3.5 to < 5 | Intermediate (> 3–4.5): median survival ≈ 3.0 years |
| 5 to < 6.5 | High (> 4.5–6): median survival ≈ 1.6 years |
| ≥ 6.5 | Very high (> 6): median survival ≈ 0.8 years |
In the app it also calculates: IPSS-RA (age-adjusted, survival only).
Practical tip
Age adjustment (IPSS-RA) only changes the survival estimate, not the risk of AML transformation.
2 more practical tips in the app.
Reference
A support tool for healthcare professionals: it guides and does not replace clinical judgement.
